India's Pharma Exports Grow to $31 Billion
Operators in generics and biosimilars can watch how India's export scale and public health model are being cited as a template abroad.
Updated on Nov. 3, 2026 in Healthcare

A report in Assahifa argues that India's healthcare model can be emulated by developing economies. The report points to India's pharmaceutical exports rising to $31 billion in FY26 from $2 billion in FY21, with Indian medicines reaching over 190 countries.
Why it matters
The report frames India's pharmaceutical manufacturing scale and public health delivery as a template, which is relevant to operators in generics, contract manufacturing, and healthcare supply chains. Its growth in export value over five years signals how quickly the sector has expanded in regulated markets.
Pharmaceutical exports rose from $2 billion in FY21 to $31 billion in FY26, and India produces around 60,000 generic brands across 60 therapeutic categories. The Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana reports 600 million beneficiaries and total spending above 2 trillion rupees.
The players
Assahifa
A Moroccan newspaper whose report is the source of the claim that India's healthcare model can be emulated by developing economies.
Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana
India's national health insurance program, which the report cites for reaching 600 million beneficiaries and supporting over 130 million treatments.
The details
Indian pharmaceutical manufacturers supply highly regulated markets, including the United States and Europe, which requires compliance with demanding quality standards. The industry is moving toward higher-value production such as injectables, biosimilars, and complex formulations, a shift from commodity generics toward products with higher margins. The report's argument rests on the combination of manufacturing scale and a large public primary care network.
Timeline
FY21: pharmaceutical exports were $2 billion.
During the Covid-19 pandemic, India supplied vaccine doses to dozens of countries through the Vaccine Maitri initiative.
FY26: pharmaceutical exports reached $31 billion.
Market Landscape
The report positions India's generic drug manufacturing and public insurance program as a model for developing economies seeking similar health outcomes. The argument draws on India's role as a supplier to highly regulated markets, a position that the sector has built over the past five years.
Operators in pharmaceutical manufacturing and contract production should track the shift toward injectables and biosimilars, which the report notes is underway in Indian production. Companies in healthcare supply chains serving regulated markets should watch how compliance expectations evolve as Indian exports continue to grow.
The takeaway
India's pharmaceutical export growth from $2 billion to $31 billion over five years shows how fast a manufacturing base can scale into regulated markets. Operators in generics and biosimilars should monitor whether the move toward higher-value production continues, since it will shape margins across the sector.
Further reading
For broader context on how pharmaceutical supply chains shape healthcare access, see Healthcare.





